Cann Group (CAN.AX) Stock Price
Cann Group Price
Revenue has compounded at 79.5% per year over the past 11 years to 8.56 M AUD. Cann Group's net margin stands at 237.1%, up from -412.9% several years earlier.
Cann Group stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cann Group business model & stock analysis
Frequently asked questions about Cann Group
Cann Group Ltd is an Australian company that operates in the medicinal cannabis industry. Its business model revolves around cultivation, manufacturing, and distribution of pharmaceutical-grade cannabis products and providing services to the medicinal cannabis sector. With a focus on research and development, Cann Group aims to support healthcare professionals and patients by developing high-quality therapeutic products derived from cannabis plants. The company's expertise lies in the production of standardized cannabis cultivars, extraction, and development of new formulations to meet the evolving needs of the medical industry. Cann Group Ltd strives to establish itself as a leading player in the medicinal cannabis market.
Cann Group Ltd is primarily active in the cannabis industry.
The main competitors of Cann Group Ltd in the market include other companies involved in the production and distribution of medical cannabis and cannabis-related products. Some significant competitors of Cann Group Ltd may include AusCann Group Holdings Ltd, Althea Group Holdings Ltd, and Little Green Pharma Ltd. These companies operate in the same industry and focus on the cultivation, manufacturing, and sale of medical cannabis products. Cann Group Ltd competes with these companies to gain market share, secure partnerships, and expand their customer base in the rapidly growing cannabis industry.
Cann Group Ltd is an Australian company that specializes in cultivating and producing medical cannabis. Established in 2014, Cann Group was the first to be granted a license to cultivate and research cannabis for medicinal purposes in Australia. With a strong commitment to quality and compliance, the company has built state-of-the-art facilities and established strategic partnerships to expand its operations. Cann Group is dedicated to providing safe and effective cannabis-based products to improve patient outcomes and is at the forefront of the rapidly growing medicinal cannabis industry in Australia.
Cann Group Ltd has achieved several significant milestones in its operations. Firstly, the company became the first Australian business to obtain a license to cultivate medicinal cannabis for research purposes in 2017. This achievement positioned Cann Group Ltd as a pioneer in the country's emerging medicinal cannabis industry. Additionally, the company successfully completed its first commercial cannabis harvest in 2018, marking another important milestone. Furthermore, Cann Group Ltd obtained its crucial Manufacture License in 2019, allowing the company to produce and distribute medicinal cannabis products in Australia. These milestones highlight Cann Group Ltd's commitment to advancing the availability and quality of medicinal cannabis within the country's market.
Cann Group Ltd is primarily present in Australia.
Cann Group Ltd, a leading Australian medicinal cannabis company, embodies a strong set of values and corporate philosophy. The company is committed to producing high-quality medical cannabis products to improve the lives of patients. Cann Group values innovation and sustainability, constantly seeking new ways to enhance their cultivation and manufacturing processes. With a focus on research and development, they aim to continually expand their product offerings and provide effective and safe treatments. Cann Group Ltd prides itself on its dedication to investors, transparency, and regulatory compliance, ensuring a trustworthy and reliable approach to business.
5 analysts currently rate the Cann Group stock: 4 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Cann Group share trades at 0.00 EUR (0.01 AUD).
The Cann Group share (CAN.AX) is listed on 3 stock exchanges, including: ASX (CAN.AX), Frankfurt (CVJ.F).
Cann Group Ltd is an Australian company specializing in the medical cannabis market. Its business model involves producing, developing, and distributing cannabis for medical use. The company serves various segments, such as the market for human medical products, the veterinary sector, and the recreational and wellness sector. The company is well positioned to benefit from the growing demand for medical cannabis, CBD products for pets, and recreational products.
The revenue of Cann Group is 8.56 M AUD. This figure is based on current financial data and reflects the company's business performance.
The profit of Cann Group is 20.30 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Cann Group is currently 0.36. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cann Group stock.
The price-to-sales ratio (P/S) of Cann Group is currently 0.85. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cann Group stock.
The Eulerpool Quality Score for Cann Group is 3/10.
The ISIN of Cann Group is AU000000CAN2. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Cann Group is A2DSUQ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Cann Group is CAN.AX. The ticker symbol is used to trade Cann Group shares on the stock exchange.
Cann Group stock
Cann Group Peer Group
Cann Group Ticker
Cann Group FIGI
All fundamentals and in-depth analysis of Cann Group
Our stock analysis for Cann Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cann Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.